Veltist is excited to announce a major funding milestone that will pave the way for revolutionary advancements in abdominal surgery safety. The company has successfully raised 160,000 dollars, a significant achievement that underscores the confidence investors have in our innovative product, AnastoSeal by Veltist. This cutting-edge sealing technology has been meticulously engineered to significantly reduce the risk of post-surgical digestive leaks, a common complication in abdominal surgeries, and to help prevent the occurrence of sepsis—a life-threatening condition that can arise when infections are not adequately controlled. By focusing on these critical areas, AnastoSeal aims to enhance patient outcomes and streamline recovery processes, thereby reducing both healthcare costs and the emotional and physical toll on patients.
The infusion of capital will be strategically utilized to accelerate our research and development efforts, expand our clinical trials, and further refine the technology to ensure it meets the rigorous demands of modern surgical practices. Our team is also planning to enhance production capabilities and increase outreach to surgical centers worldwide, ensuring that this breakthrough innovation can benefit as many patients as possible. With this financial boost, Veltist is well-positioned to become a leader in the advancement of surgical safety technologies, setting new industry standards. We are proud of this achievement and excited by the opportunities it brings to revolutionize post-operative care. If you are interested in learning more about AnastoSeal by Veltist or exploring potential collaborations, please feel free to contact us at alexandre.anthis@empa.ch.
